BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 27598385)

  • 1. Incremental Value of a Dedicated Head and Neck Acquisition during 18F-FDG PET/CT in Patients with Differentiated Thyroid Cancer.
    Ciappuccini R; Aide N; Blanchard D; Rame JP; de Raucourt D; Michels JJ; Babin E; Bardet S
    PLoS One; 2016; 11(9):e0162482. PubMed ID: 27598385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. F-18-Dopa Positron Emission Tomography/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent/Recurrent Disease of Medullary Thyroid Cancer Patients.
    Terroir M; Caramella C; Borget I; Bidault S; Dromain C; El Farsaoui K; Deandreis D; Grimaldi S; Lumbroso J; Berdelou A; Hadoux J; Hescot S; Hartl D; Baudin E; Schlumberger M; Leboulleux S
    Thyroid; 2019 Oct; 29(10):1457-1464. PubMed ID: 31530235
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of FDG-PET computed tomography for surgery of recurrent or persistent differentiated thyroid carcinoma.
    Weber T; Ohlhauser D; Hillenbrand A; Henne-Bruns D; Reske SN; Luster M
    Horm Metab Res; 2012 Nov; 44(12):904-8. PubMed ID: 22791600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-FDG-PET/CT in Patients Affected by Differentiated Thyroid Carcinoma with Positive Thyroglobulin Level and Negative 131I Whole Body Scan. It's Value Confirmed by a Bicentric Experience.
    Bertagna F; Albano D; Bosio G; Piccardo A; Dib B; Giubbini R
    Curr Radiopharm; 2016; 9(3):228-234. PubMed ID: 27210819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The additive clinical value of 18F-FDG PET/CT in defining the recurrence of disease in patients with differentiated thyroid cancer who have isolated increased antithyroglobulin antibody levels.
    Ozkan E; Soydal C; Araz M; Aras G; Ibis E
    Clin Nucl Med; 2012 Aug; 37(8):755-8. PubMed ID: 22785502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
    Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
    Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of a dedicated protocol using a small-voxel PSF reconstruction for head-and-neck
    Ciappuccini R; Desmonts C; Licaj I; Blanc-Fournier C; Bardet S; Aide N
    EJNMMI Res; 2018 Dec; 8(1):104. PubMed ID: 30511173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent thyroid cancer diagnosis: ROC study of the effect of a high-resolution head and neck 18F-FDG PET/CT scan.
    Chatziioannou SN; Georgakopoulos AT; Pianou NK; Kafiri GT; Pavlou SN; Kallergi M
    Acad Radiol; 2014 Jan; 21(1):58-63. PubMed ID: 24331265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-fluorodeoxyglucose positron emission tomography-computed tomography for suspected recurrent papillary thyroid cancer: early experience at Sunnybrook Health Sciences Centre.
    Dahele M; Ung YC; Ehrlich L; Silverberg J; Balogh J; Wong CS
    J Otolaryngol Head Neck Surg; 2008 Oct; 37(5):712-7. PubMed ID: 19128681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies.
    Nakajo M; Nakajo M; Jinguji M; Tani A; Kajiya Y; Tanabe H; Fukukura Y; Nakabeppu Y; Koriyama C
    Radiology; 2013 Jun; 267(3):891-901. PubMed ID: 23468571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of neck recurrence in patients with differentiated thyroid cancer: comparison of ultrasound, contrast-enhanced CT and (18)F-FDG PET/CT using surgical pathology as a reference standard: (ultrasound vs. CT vs. (18)F-FDG PET/CT in recurrent thyroid cancer).
    Seo YL; Yoon DY; Baek S; Ku YJ; Rho YS; Chung EJ; Koh SH
    Eur Radiol; 2012 Oct; 22(10):2246-54. PubMed ID: 22562091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic role of F-18 FDG PET/CT for preoperative lymph node staging in thyroid cancer patients; A systematic review and metaanalysis.
    Kim DH; Kim SJ
    Clin Imaging; 2020 Sep; 65():100-107. PubMed ID: 32387798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of 18F-FDG PET/CT in detecting suspected recurrence or metastasis in well-differentiated thyroid carcinoma patients with negative diagnostic total body scan in Thailand: a decision analysis.
    Khiewvan B; Nopmaneejumruslers C; Pusuwan P; Tuchinda P; Tojinda N; Ubolnuch K
    J Med Assoc Thai; 2013 Oct; 96(10):1350-64. PubMed ID: 24350419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-PET ultrasound improves specificity of 18F-FDG-PET for recurrent differentiated thyroid cancer while maintaining sensitivity.
    Biermann M; Kråkenes J; Brauckhoff K; Haugland HK; Heinecke A; Akslen LA; Varhaug JE; Brauckhoff M
    Acta Radiol; 2015 Nov; 56(11):1350-60. PubMed ID: 25770086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of 8F-FDG PET/CT in well differentiated thyroid carcinoma with high serum antithyroglobulin antibody.
    Kingpetch K; Pipatrattana R; Tepmongkol S; Sirisalipoch S; Chaiwatanarat T
    J Med Assoc Thai; 2011 Oct; 94(10):1238-44. PubMed ID: 22145510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility of FDG-PET/CT for the initial diagnosis of papillary thyroid cancer.
    Kim H; Na KJ; Choi JH; Ahn BC; Ahn D; Sohn JH
    Eur Arch Otorhinolaryngol; 2016 Jun; 273(6):1569-76. PubMed ID: 25971994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of combined FDG-PET/CT and MRI on the detection of local recurrence and nodal metastases in thyroid cancer.
    Hempel JM; Kloeckner R; Krick S; Pinto Dos Santos D; Schadmand-Fischer S; Boeßert P; Bisdas S; Weber MM; Fottner C; Musholt TJ; Schreckenberger M; Miederer M
    Cancer Imaging; 2016 Nov; 16(1):37. PubMed ID: 27809936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between clinicopathologic factors and FDG avidity in radioiodine-negative recurrent or metastatic differentiated thyroid carcinoma.
    Ha LN; Iravani A; Nhung NT; Hanh NTM; Hutomo F; Son MH
    Cancer Imaging; 2021 Jan; 21(1):8. PubMed ID: 33413689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
    Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
    Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.